CorMedix Inc expected to post a loss of 28 cents a share - Earnings Preview

CorMedix

07/05/2024 18:26

* CorMedix Inc  CRMD.OQ   CRMD.O  is expected to show no
change in
quarterly revenue when it reports  results on May 9 for the
period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for CorMedix Inc is for a
loss
of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CorMedix
Inc is
$12.00​, above​ its last closing price of $5.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.20       -0.20      -0.26     Missed  -28.9
 Sep. 30 2023  -0.20       -0.21      -0.17     Beat    18.2
 Jun. 30 2023  -0.23       -0.24      -0.25     Missed  -3.6​
 Mar. 31 2023  -0.20       -0.20      -0.24     Missed  -20
 ​​Dec.                    -0.19      -0.20     Missed  -7
 31 2022                                                
 Sep. 30 2022  -0.22       -0.23      -0.17     Beat    25.5​
 Jun. 30 2022  -0.20       -0.21      -0.19     Beat    8.1
 Mar. 31 2022  -0.22       -0.22      -0.18     Beat    18.2
 This summary was machine generated May 7 at 17:26 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)